Lupin's Joint Airways Initiative surpasses 10,000 patients

Lupin receives approval from TGA Australia for Tiotropium Dry Powder

Tiotropium (as bromide monohydrate) 18 micrograms powder for inhalation in capsule

Lupin launches Luforbec 100/6 for adult asthma and COPD treatment in Germany

Luforbec® 100/6 pMDI aims to provide comprehensive support to patients and healthcare professionals

GenWorks launches FenomPro breath analyser

Ensures efficient testing of FeNO as it is a simple tool for the diagnosis, screening & monitoring of Asthma patients

Lonza upgrades powder characterization capabilities at Tampa

The new powder flow tester can characterize powder flow properties, offering valuable insight for pharmaceutical processing and formulation

75% of asthma patients have worse symptoms during cold or flu

Asthma patients are more likely to have an asthma attack during winter

Alkem to spread awareness through “The Healthy Lungs”

Though lungs do not have the celebrity status as the heart, they are one of the most important and delicate organs of the human body

USFDA completes inspection at Aurolife Pharma’s Raleigh unit

The unit has filed 2 Derma products and 1 MDI product.

Lupin receives UK MHRA Approval of Lutio for treatment of COPD

Lutio has the potential to offer significant cost savings when available to UK patients.

Lonza to expand inhalation capabilities at Tampa site

Lonza to expand inhalation services by adding capabilities at its Tampa (US) site as part of its continued focus on providing bioavailability enhancement series for global customers